🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Linaglip-M 5/1000 ER Tablet is a combination of two medicines used to treat high blood sugar levels in people with type 2 diabetes mellitus. It is effective in preventing serious complications such as kidney damage, blindness, heart attack, or stroke. The dose of the medicine will depend on your condition, blood sugar levels, and other medications you are taking. It is recommended to take this medicine with meals to avoid an upset stomach. You should take it regularly at the same time each day and not stop it unless your doctor advises you to. A healthy diet and regular exercise are essential for managing diabetes, along with taking this medicine.
It is unsafe to consume alcohol with Linaglip-M 5/1000 ER Tablet.
It is unknown whether Linaglip-M 5/1000 ER Tablet might harm an unborn baby. As a result, unless prescribed by your doctor, it should not be taken during pregnancy.
It is unknown whether Linaglip-M 5/1000 ER Tablet may pass through breast milk. As a result, it should only be taken during breastfeeding if deemed essential by a physician.
Driving Ability may be affected if your blood sugar is too low or too high. Do not drive if these symptoms occur.
Linaglip-M 5/1000 ER Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
Linaglip-M 5/1000 ER Tablet is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
Linaglip-M 5/1000 ER Tablet contains two diabetes medications: metformin and linagliptin. Metformin is a kind of diabetes drug known as a biguanide. It acts by decreasing glucose synthesis in the liver, slowing glucose absorption from the intestines, and boosting insulin sensitivity. Linagliptin is a DPP-4 inhibitor that acts by enhancing pancreatic insulin release while reducing blood sugar-raising chemicals. This lowers fasting and postmeal sugar levels. They work together to improve blood sugar management.
Linaglip-M is a medication used to help manage blood sugar levels in adults with type 2 diabetes when both linagliptin and metformin are deemed necessary. It should be taken alongside a healthy diet and exercise routine. However, this medication should not be used to treat type 1 diabetes or diabetic ketoacidosis. Additionally, it has not been studied in patients with a history of pancreatitis, and caution should be taken if prescribed to patients with this medical history. It is important to follow your healthcare provider's instructions and guidelines when taking this medication.
Linaglip-M is a combination of two drugs used to treat type 2 diabetes mellitus. The two drugs, Linagliptin and Metformin, work together to improve glycemic control in patients.
Linagliptin is a DPP-4 inhibitor that blocks the degradation of incretin hormones, GLP-1 and GIP. By doing so, it increases insulin release in a glucose-dependent manner and reduces glucagon levels, leading to better glucose homeostasis.
Metformin, on the other hand, reduces both basal and postprandial glucose levels. It achieves this by several mechanisms such as decreasing hepatic glucose production, improving peripheral glucose uptake, delaying intestinal glucose absorption, and increasing intracellular glycogen synthesis.
This combination of medications offers complementary mechanisms of action to effectively lower blood glucose levels without causing hypoglycemia or weight gain. However, it is important to follow a healthy diet and exercise routine alongside taking the medication to achieve optimal glycemic control. As with any medication, it may not be suitable for everyone, and your doctor will monitor your blood glucose levels and adjust the dose accordingly.
It is important to take Linaglip-M 5/1000 ER Tablet as directed by your physician. It is recommended to take the medicine after meals and to swallow it whole with a glass of water. Do not crush or chew the tablet. The appropriate dose and duration of therapy will be determined by your doctor based on factors such as your age, body weight, and disease condition. Do not discontinue the medication without consulting with your doctor.
Linagliptin & Metformin can potentially interact with other drugs, and careful monitoring and dose adjustment may be necessary. Cationic drugs that are eliminated by renal tubular secretion may compete with Metformin for the same transport systems, and caution should be exercised when prescribing these drugs with Linagliptin & Metformin. Carbonic anhydrase inhibitors and alcohol can also increase the risk of metabolic acidosis when taken with Linagliptin & Metformin.
Rifampin, a strong P-GP or CYP 3A4 enzyme inducer, can reduce Linagliptin exposure and lower its efficacy, so it is not recommended to take these drugs together. Patients taking insulin secretagogues or insulin with Linagliptin & Metformin may need lower doses of these medications to prevent hypoglycemia.
Certain medications can cause hyperglycemia and affect glycemic control, so patients taking Linagliptin & Metformin should be closely monitored if they are also taking these medications. Similarly, if these medications are discontinued, patients should be monitored for hypoglycemia.
This combination of Linagliptin and Metformin is not recommended for patients who have a renal impairment (e.g., serum creatinine >1.5 mg/dL for men, >1.4 mg/dL for women, or abnormal creatinine clearance), which can be caused by conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. This combination is also not recommended if you have acute or chronic metabolic acidosis, such as diabetic ketoacidosis. Insulin should be used to treat diabetic ketoacidosis in the event of a previous history of hypersensitivities to Linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity. It is also not recommended if you are allergic to Metformin.
Pregnancy: Linagliptin & Metformin combination is pregnancy Category B. Linagliptin & Metformin combination tablets should be used during pregnancy only if clearly needed. But the limited data on the combination of Linagliptin & Metformin combination extended-release tablet use in pregnant women are not sufficient to inform a Linagliptin & Metformin extended-release combination - associated or Linagliptin-associated risk for major birth defects and miscarriage.
Nursing mothers: There is no information regarding the presence of both Linagliptin & Metformin combination and Linagliptin & Metformin combination extended-release tablet or Linagliptin in human milk, the effects on the breastfed infant, or the effects on milk production.
Store at 25°C and dry place, protect from light. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.